药物对比
Vildagliptin vs Lixisenatide
Vildagliptin与Lixisenatide：治疗2型糖尿病的口服DPP-4抑制剂与注射用GLP-1激动剂。权衡A1C控制、胃肠道副作用、体重减轻，以及注射与口服药片的便利性。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered when selecting between an oral DPP-4 inhibitor and an injectable GLP-1 agonist for type 2 diabetes patients needing better glycemic control or weight management.
结论
Lixisenatide typically offers stronger A1C reduction and weight loss while Vildagliptin provides oral convenience with a milder GI side-effect profile.
全部药物对比